ACT-HIB 30 MCG / 0.5 ML
TETANUS PROTEIN : 30 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 10 MCG / 0.5 ML · DIN 01959034 · SANOFI PASTEUR LIMITED
Health Canada status: MARKETED
What is ACT-HIB?
ACT-HIB 30 MCG / 0.5 ML contains TETANUS PROTEIN : 30 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 10 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 01959034, held by SANOFI PASTEUR LIMITED, supplied as KIT ; POWDER FOR SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 14-Jul-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT-HIB used for?
Act-HIB® is indicated for the active immunization of children 2 months of age and older for the prevention of invasive disease caused by Haemophilus influenzae type b. Routine immunization against invasive disease caused by H. influenzae type b in infants and children between 2 to 59 months of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01959034 |
|---|---|
| Brand name | ACT-HIB |
| Generic / active ingredient | TETANUS PROTEIN : 30 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 10 MCG / 0.5 ML |
| Manufacturer | SANOFI PASTEUR LIMITED |
| Strength | 30 MCG / 0.5 ML |
| Dosage form | KIT ; POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AG01 HEMOPHILUS INFLUENZAE B, PURIFIED ANTIG. CONJUGATED |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Jul-2006 |
| Original market date | 1992-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Available in packages containing five single-dose vials of Act-HIB® and five x 0.5 mL (single dose vials of Sanofi Pasteur Limited’s DILUENT, 0.4% Saline for reconstitution of Act-HIB®. Also supplied in packages containing five single dose vials of Act-HIB® and five x 0.5 mL (single dose) vial of Sanofi Pasteur Limited's QUADRACEL® to be used for reconstitution in place of the Act-HIB® diluent and sold under the tradename PENTACEL®. Also supplied in one or five dose packages containing either one or five single dose vials of Act-HIB® and one or five x 0.5 mL (single dose) vials of Sanofi Pasteur Limited's TRIPACEL® to be used for reconstitution in place of the Act-HIB® diluent and sold under the tradename ACTACEL®.
What can be used instead?
Other Canadian products sharing ATC code J07AG01 HEMOPHILUS INFLUENZAE B, PURIFIED ANTIG. CONJUGATED. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LIQUID PEDVAXHIB | 125 MCG / 0.5 ML | SUSPENSION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02235721 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.